- Cell-based medicines group MaxCyte said it had entered into a research agreement with Gilead subsidiary Kite.

Under the terms of the pact, Kite would use MaxCyte's technology to enable non-viral cell engineering.

'We're excited to provide Kite the ability to leverage our versatile cell engineering platform to enable gene-editing technologies for research and development of important new therapeutics,' chief executive Doug Doerfler said.

'This agreement further underlines MaxCyte's position as a leader in non-viral cell engineering for cell therapies.'

At 8:03am: [LON:MXCT] MaxCyte Inc share price was +1p at 199p

Story provided by